Adenoid Cystic Carcinoma Researchfoundation
- Assets
- $2.7m
- Revenue
- $1.4m
- Investments
- $0.0
- Employees
- 2
- Location
- Needham, MA
- Founding
- 03/2006
- Data as of
- 12/2022
- EIN
- 20-6745475
Organization Overview
Adenoid Cystic Carcinoma Researchfoundation is located in Needham, MA. The organization was established in 2006. According to its NTEE Classification (H12) the organization is classified as: Fund Raising & Fund Distribution, under the broad grouping of Medical Research and related organizations. As of 12/2022, Adenoid Cystic Carcinoma Researchfoundation employed 2 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Adenoid Cystic Carcinoma Researchfoundation is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2022, Adenoid Cystic Carcinoma Researchfoundation generated $1.4m in total revenue. The organization has seen a slow decline revenue. Over the past 7 years, revenues have fallen by an average of (2.6%) each year. All expenses for the organization totaled $1.6m during the year ending 12/2022. As we would expect to see with falling revenues, expenses have declined by (1.5%) per year over the past 7 years. You can explore the organizations financials more deeply in the financial statements section below.
Since 2015, Adenoid Cystic Carcinoma Researchfoundation has awarded 59 individual grants totaling $5,150,365. If you would like to learn more about the grant giving history of this organization, scroll down to the grant profile section of this page.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2022
Describe the Organization's Mission:
Part 3 - Line 1
SUPPORTING RESEARCH INTO THE TREATMENT AND CURE OF ADENOID CYSTIC CARCINOMA.
Describe the Organization's Program Activity:
Part 3 - Line 4a
TRANSLATION TO THE CLINIC: ACCRF SUPPORTS AND COORDINATES RESEARCH INTO TREATMENTS MOST LIKELY TO LEAD TO CLINICAL EBENFIT FOR ADENOID CYSTIC CARCINOMA PATIENTS. DRUG DISCOVERY, DRUG DEVELOPMENT, PRECLINICAL DRUG SCREENING AND CORRELATIVE STUDIES ARE CRUCIAL TO THE INITIATION AND OPTIMAL CONDUCT OF CLINICAL TRIALS.
BASIC RESEARCH: ACCRF SUPPORTS AND COORDINATES THE DESCRIPTIVE AND FUNCTIONAL STUDIES THAT IDENTIFY MOLECULAR TARGETS AND PATHWAYS THAT PERMIT ADENOID CYSTIC CARCINOMA TO PROGRESS. BY FOCUSING ON THE MECHANISMS OF ACTION, RESEARCHERS MAY DISCOVER MORE QUICKLY THE ACHILLES' HEEL OF THE DISEASE.
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
Jeffrey A Kaufman Executive Director/board Chair | OfficerTrustee | 50 | $150,000 |
Thomas Dilenge Board Vice Chair | OfficerTrustee | 5 | $0 |
Ralph Mollis Treasurer | OfficerTrustee | 5 | $0 |
Marnie A Kaufman Director & CFO | Trustee | 25 | $0 |
Elizabeth Wehlage Director | Trustee | 5 | $0 |
Lisa Bakri Director | Trustee | 5 | $0 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Federated campaigns | $0 |
| Membership dues | $0 |
| Fundraising events | $0 |
| Related organizations | $0 |
| Government grants | $0 |
| All other contributions, gifts, grants, and similar amounts not included above | $807,996 |
| Noncash contributions included in lines 1a–1f | $0 |
| Total Revenue from Contributions, Gifts, Grants & Similar | $807,996 |
| Total Program Service Revenue | $551,076 |
| Investment income | $11,819 |
| Tax Exempt Bond Proceeds | $0 |
| Royalties | $0 |
| Net Rental Income | $0 |
| Net Gain/Loss on Asset Sales | $15,764 |
| Net Income from Fundraising Events | $0 |
| Net Income from Gaming Activities | $0 |
| Net Income from Sales of Inventory | $0 |
| Miscellaneous Revenue | $0 |
| Total Revenue | $1,386,655 |
| Statement of Expenses | |
|---|---|
| Grants and other assistance to domestic organizations and domestic governments. | $467,712 |
| Grants and other assistance to domestic individuals. | $0 |
| Grants and other assistance to Foreign Orgs/Individuals | $62,142 |
| Benefits paid to or for members | $0 |
| Compensation of current officers, directors, key employees. | $150,000 |
| Compensation of current officers, directors, key employees. | $34,944 |
| Compensation to disqualified persons | $0 |
| Other salaries and wages | $125,531 |
| Pension plan accruals and contributions | $0 |
| Other employee benefits | $0 |
| Payroll taxes | $20,788 |
| Fees for services: Management | $0 |
| Fees for services: Legal | $0 |
| Fees for services: Accounting | $20,750 |
| Fees for services: Lobbying | $0 |
| Fees for services: Fundraising | $0 |
| Fees for services: Investment Management | $0 |
| Fees for services: Other | $2,576 |
| Advertising and promotion | $0 |
| Office expenses | $37,805 |
| Information technology | $0 |
| Royalties | $0 |
| Occupancy | $0 |
| Travel | $0 |
| Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
| Conferences, conventions, and meetings | $2,872 |
| Interest | $0 |
| Payments to affiliates | $0 |
| Depreciation, depletion, and amortization | $0 |
| Insurance | $3,137 |
| All other expenses | $0 |
| Total functional expenses | $1,618,196 |
| Balance Sheet | |
|---|---|
| Cash—non-interest-bearing | $134,305 |
| Savings and temporary cash investments | $2,225,840 |
| Pledges and grants receivable | $0 |
| Accounts receivable, net | $222,684 |
| Loans from Officers, Directors, or Controlling Persons | $0 |
| Loans from Disqualified Persons | $0 |
| Notes and loans receivable | $0 |
| Inventories for sale or use | $0 |
| Prepaid expenses and deferred charges | $76,878 |
| Net Land, buildings, and equipment | $0 |
| Investments—publicly traded securities | $0 |
| Investments—other securities | $0 |
| Investments—program-related | $0 |
| Intangible assets | $0 |
| Other assets | $0 |
| Total assets | $2,659,707 |
| Accounts payable and accrued expenses | $89,190 |
| Grants payable | $25,000 |
| Deferred revenue | $22,698 |
| Tax-exempt bond liabilities | $0 |
| Escrow or custodial account liability | $0 |
| Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
| Secured mortgages and notes payable | $0 |
| Unsecured mortgages and notes payable | $0 |
| Other liabilities | $0 |
| Total liabilities | $136,888 |
| Net assets without donor restrictions | $2,522,819 |
| Net assets with donor restrictions | $0 |
| Capital stock or trust principal, or current funds | $0 |
| Paid-in or capital surplus, or land, building, or equipment fund | $0 |
| Retained earnings, endowment, accumulated income, or other funds | $0 |
| Total liabilities and net assets/fund balances | $2,659,707 |
Grants Awarded
Over the last fiscal year, Adenoid Cystic Carcinoma Researchfoundation has awarded $467,712 in support to 7 organizations.
| Grant Recipient | Amount |
|---|---|
MD ANDERSON CANCER CENTER PURPOSE: SUPPORT FOR THE STUDY OF IMAGING FEATURES AND NATURAL HISTORY OF METASTATIC ADENOID CYSTIC CARCINOMA | $25,000 |
UNIVERSITY OF CHICAGO PURPOSE: SUPPORT FOR THE STUDY OF ORGANOID DEVELOPMENT AND INTEGRATED GENOMIC CHARACTERIZATION OF ACC | $25,000 |
DANA-FARBER PURPOSE: SUPPORT FOR THE STUDY OF DIRECT GENE-REGULATORY FUNCTIONS OF MYB/MYBL1 FUSION ONCOPROTEINS | $25,000 |
DANA-FARBER PURPOSE: SUPPORT FOR THERAPEUTIC DRUG SCREENING USING A NOVEL IMPLANTABLE MICRODEVICE (IMD) IN ADENOID CYSTICCARCINOMA (ACC): A WINDOW OF OPPORTUNITY STUDY | $25,000 |
MASSACHUSETTS GENERAL HOSPITAL PURPOSE: SUPPORT FOR MGH ACC CLINICAL DATABASE | $25,000 |
DANA-FARBER PURPOSE: SUPPORT FOR THE STUDY OF TARGETED PROTEIN DEGRADATION APPROACHES TO DEFINE THE MOLECULAR MECHANISMS OF MYB ONCOPROTEINS IN ACC | $242,712 |